Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202665 (US10245267, Example 10 | US10709712, Example 10 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.118 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202665 (US10245267, Example 10 | US10709712, Example 10 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.120 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202696 (US10245267, Example 43 | US10709712, Example 42 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.137 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202656 (US10245267, Example 1 | US10709712, Example 1 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.140 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202696 (US10245267, Example 43 | US10709712, Example 42 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.140 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202656 (US10245267, Example 1 | US10709712, Example 1 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.144 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202772 (US10245267, Example 119 | US10709712, Example 119 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.270 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202772 (US10245267, Example 119 | US10709712, Example 119 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.270 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202771 (US10245267, Example 118 | US10709712, Example 118 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.308 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202771 (US10245267, Example 118 | US10709712, Example 118 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.310 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202697 (US10245267, Example 42 | US10709712, Example 43 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.376 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202718 (US10245267, Example 111 | US10709712, Example 111 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202764 (US10245267, Example 64 | US10709712, Example 64 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.403 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202661 (US10245267, Example 6 | US10709712, Example 6 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.408 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202661 (US10245267, Example 6 | US10709712, Example 6 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.410 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202845 (US10245267, Example 198 | US10709712, Example 198 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.455 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202845 (US10245267, Example 198 | US10709712, Example 198 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202717 (US10245267, Example 63 | US10709712, Example 63 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.508 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202717 (US10245267, Example 63 | US10709712, Example 63 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.510 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202663 (US10709712, Example 8 | US9242969, 8 | US9242969, ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.510 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202663 (US10709712, Example 8 | US9242969, 8 | US9242969, ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.514 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202668 (US10245267, Example 13 | US10709712, Example 13 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.530 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202668 (US10245267, Example 13 | US10709712, Example 13 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.533 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202666 (US10245267, Example 11 | US10709712, Example 11 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.580 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202666 (US10245267, Example 11 | US10709712, Example 11 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.580 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202843 (US10245267, Example 196 | US10709712, Example 196 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.620 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202843 (US10245267, Example 196 | US10709712, Example 196 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.621 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202698 (US10245267, Example 44 | US10709712, Example 44 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.710 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202698 (US10245267, Example 44 | US10709712, Example 44 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.714 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202669 (US10245267, Example 14 | US10709712, Example 14 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.800 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202669 (US10245267, Example 14 | US10709712, Example 14 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.803 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202718 (US10245267, Example 111 | US10709712, Example 111 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.847 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202764 (US10245267, Example 64 | US10709712, Example 64 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.850 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202663 (US10709712, Example 8 | US9242969, 8 | US9242969, ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.899 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM77059 (US10245267, Example 9 | US10709712, Example 9 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.900 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202699 (US10245267, Example 45 | US10709712, Example 45 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.02 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202699 (US10245267, Example 45 | US10709712, Example 45 | ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.02 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202662 (US10245267, Example 7 | US10709712, Example 7 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.11 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202662 (US10245267, Example 7 | US10709712, Example 7 | US...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.11 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202846 (US10245267, Example 199 | US10709712, Example 199 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.29 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202846 (US10245267, Example 199 | US10709712, Example 199 ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.29 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202657 (US10709712, Example 2 | US9242969, 2 | US9694016, ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.95 | n/a | n/a | n/a | n/a | 7.5 | 25 |
NOVARTIS AG US Patent | Assay Description Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ... | US Patent US9694016 (2017) BindingDB Entry DOI: 10.7270/Q2MC8X6W | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RAF proto-oncogene serine/threonine-protein kinase [1-324] (Homo sapiens (Human)) | BDBM202657 (US10709712, Example 2 | US9242969, 2 | US9694016, ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.95 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description Final assay conditions were 4 pM cRaf, 3 uM ATP, 10 nM biotin tagged MEK1 kinase dead protein substrate. Reactions were performed in Greiner384 well ... | US Patent US9242969 (2016) BindingDB Entry DOI: 10.7270/Q2VT1QXT | |||||||||||
More data for this Ligand-Target Pair |